entresto
CCG Briefing on Sacubitril Valsartan (Entresto®) NICE Technology Appraisal Guidance TA388
This briefing is designed to inform CCGs of the implications of NICE TAG 388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction.
Sacubitril valsartan (Entresto®) – Heart failure
NICE have recently published their advice on use of Sacubitril valsartan (Entresto®) for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Entresto® includes both a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (ARB; valsartan).
The complementary cardiovascular benefits of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan.